在I期临床试验中发现双剂剂量 - - 扩展快速招生设计
1Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Statistics in medicine
|July 29, 2024
概括
快速注册双剂设计 (REDD) 是一项用于I期临床试验的新方法. 它通过允许在不等待完整的毒性评估的情况下进行治疗分配来加速患者招募,保持MTD估计质量.
科学领域:
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
- 生物统计学 生物统计学
背景情况:
- 双剂治疗在临床试验中越来越常见.
- 有效的剂量检测对于药物开发的早期阶段至关重要.
研究的目的:
- 引入和评估用于I期剂量确定研究的快速注册双剂设计 (REDD).
- 根据BOIN和POCRM等既有方法评估REDD的表现.
- 为了确定REDD是否会影响最大耐受剂量 (MTD) 估计质量.
主要方法:
- 进行了模拟,将REDD与贝叶斯最佳区间 (BOIN) 和部分顺序持续重新评估方法 (POCRM) 设计进行比较.
- REDD允许在不等待当前队列毒性评估完成之前注册患者.
- 开发了用户友好的在线应用程序,以支持REDD实施.
主要成果:
- 在各种场景中,REDD显示了与BOIN和POCRM相比的平均绩效.
- 晚期发作的毒性评估表明,REDD不会显著地影响MTD估计质量.
- REDD显著减少了临床试验招生时间.
结论:
- 在I期双剂试验中,REDD是一种可行且有效的替代剂量确定方法.
- 该设计在有效的入学和准确的MTD估计之间提供了平衡.
- REDD是可以理解的,易于实施,并加速试验时间表.
更多相关视频
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.6K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
相关概念视频
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Drug Discovery: Overview
7.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.7K
Preclinical Development: Overview
4.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.3K
Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
Dose-Response Relationship: Overview
3.1K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.1K
One-Compartment Open Model for IV Bolus Administration: General Considerations
178
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
178
